Pliant Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$149.3MTTM through 30 Jun 2026
Free Cash Flow -$70.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-101.6%ROE
-78.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio12.00x
Net Debt-$170.9Mnet cash position
Cash & Equivalents$24.9M
Quality Metrics
Altman Z-Score-7.45
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$1.50TTMFY2025: $-2.43
Dividend
No dividend
Capital Allocation
R&D Spend$63.8M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.